OKYO Pharma (OKYO) CEO receives 15,000-share stock award

Rhea-AI Filing Summary

OKYO Pharma Ltd reported that CEO Robert John Dempsey received a grant or award of 15,000 shares of common stock on July 22, 2026 at a reported value of $1.539 per share. Following this non-derivative acquisition, he directly holds 15,000 common shares. The transaction was not made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 15,000 shares

Net Buy 1 txn

Insider Dempsey Robert John

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	COMMON STOCK	15,000	$1.539	$23K

Holdings After Transaction: COMMON STOCK — 15,000 shares (Direct)

Key Figures

Shares acquired: 15,000 shares of common stock Price per share: $1.539 Shares owned after transaction: 15,000 shares +1 more

4 metrics

Shares acquired 15,000 shares of common stock Grant or award reported on July 22, 2026

Price per share $1.539 Reported value per share for the stock grant

Shares owned after transaction 15,000 shares Direct common stock holdings of Robert John Dempsey after the grant

Number of acquisition transactions 1 Non-derivative acquisition transactions reported in this Form 4

Key Terms

Grant, award, or other acquisition, non-derivative, Rule 10b5-1

3 terms

Grant, award, or other acquisition financial

"Transaction code description: "Grant, award, or other acquisition""

non-derivative financial

"Transaction type is identified as a "non-derivative" transaction"

Rule 10b5-1 regulatory

"The Rule 10b5-1 checkbox (aff_10b5_one) is marked false"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/23/2026 - 04:20 PM Accepted by SEC EDGAR 07/23/2026 - 04:20 PM Learn about SEC filing dates

FAQ

What insider transaction did OKYO (OKYO) disclose for its CEO?

OKYO Pharma disclosed that CEO Robert John Dempsey received a grant of 15,000 common shares. The non-derivative award was reported as an acquisition on July 22, 2026 at $1.539 per share, increasing his directly held stake to 15,000 OKYO shares.

How many OKYO (OKYO) shares and at what price were granted to the CEO?

Robert John Dempsey was granted 15,000 shares of OKYO Pharma common stock at a reported value of $1.539 per share. This transaction is classified as a non-derivative grant or award, rather than an open-market purchase or sale.

Was the OKYO (OKYO) CEO’s stock grant made under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox is marked false, indicating the transaction was not carried out under a pre-arranged Rule 10b5-1 trading plan. The award therefore reflects a reported, discretionary equity grant on the stated transaction date.

What is the OKYO (OKYO) CEO’s ownership after this stock award?

After the reported grant, CEO Robert John Dempsey directly owns 15,000 shares of OKYO Pharma common stock. The Form 4 shows these as his total directly held non-derivative common shares following the July 22, 2026 acquisition transaction.

Is the OKYO (OKYO) CEO’s reported transaction derivative or non-derivative?

The transaction is classified as non-derivative, involving common stock directly rather than options or other derivative securities. It is coded as a “Grant, award, or other acquisition,” indicating an equity award of shares instead of an option exercise.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dempsey Robert John

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON X0 W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	07/22/2026		A		15,000	A	$1.539	15,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Robert Dempsey	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)